Knopp Biosciences raises $5M, pivots flailing ALS drug to aim new indication
December 12, 2014 - als
A lot of hopes were pinned on regulating dexpramipexole to provide those with ALS. But it the small proton drug, suspicion to say mitochondrial function, flopped in Biogen Idec’s Phase 3 trials final year: Though fast-tracked in 2009 for a indication, it failed to uncover any statistical efficiency in improving a symptoms or lifespan of patients with Lou Gehrig’s disease.
That said, Pittsburgh startup Knopp Biosciences is still actively study dexpramipexole: It only lifted about $5 million in a new fundraise from 18 investors, and has a go-ahead from a NIH to investigate a devalue in a horde of other diseases – including ALS.
Of course, this is tiny potatoes for a association that lifted $140 million in 2010 – in a days when dexpramipexole was earnest for ALS – though this new appropriation turn shows that investors still have some faith in a molecule’s effifacy.
Here’s Knopp’s pipeline:
The NIH’s National Institute of Allergy and Infectious Diseases is operative with Knopp to control a clinical hearing of dexpramipexole in hypereosinophilic syndrome, or HES, that causes mixed organ damage.
Dexpramipexole is closely associated to pramipexole, a dopamine agonist ordinarily used in treating Parkinson’s illness and nervous legs syndrome underneath trade names Mirapex, Mirapexin and Sifrol.
Hear a latest attention news first
Get the daily newsletter or follow us.
Please enter your email below: